UPDATE: UBS Starts Kymera Therapeutics (KYMR) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kymera Therapeutics (KYMR) PT Lowered to $67 at Morgan Stanley
May 18, 2021 3:08 AM EDTMorgan Stanley analyst Vikram Purohit lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $67.00 (from $69.00) while maintaining a Equalweight rating.... More
